Psychiatry Research
August 2018
Xiaoyin Ke, Yi Ding, Ke Xu et al.
The aim of this study was to examine the cognitive function in chronic ketamine users. Factors correlated to cognition impairments were analyzed. Sixty-three chronic ketamine users and 65 healthy subjects were recruited. Cognitive function was assessed by using immediate/delayed visual reproduction (IVR/DVR) tasks, immediate/delayed logical memory (ILM/DLM) tasks, Stroop test, Wisconsin card...
Human Psychopharmacology: Clinical and Experimental
May 2018
Minling Zhang, Hongbo He, Yuping Ning et al.
Growth factors play an important role in brain development. Whether epidermal growth factor (EGF) plays a role in the pathophysiology of ketamine related disorders is unexplored. In this study, we examined the serum levels of EGF in chronic ketamine users as compared with healthy controls. The possible correlation between serum EGF levels with the demographic, ketamine use characteristics and...
Schizophrenia Research
November 14, 2015
Ni Fan, Yayan Luo, Ke Xu et al.
Objective Exposing to NMDAR receptor antagonists, such as ketamine, produces schizophrenia-like symptoms in humans and deteriorates symptoms in schizophrenia patients. Meanwhile, schizophrenia is associated with alterations of cytokines in the immune system. This study aims to examine the serum TNF-α, IL-6 and IL-18 levels in chronic human ketamine users as compared to healthy subjects. The...
Shanghai archives of psychiatry
June 1, 2015
Ni Fan, Ke Xu, Yuping Ning et al.
Background: Ketamine is an increasingly popular drug of abuse in China but there is currently no method for classifying the psychological effects of ketamine in individuals with ketamine dependence. Aim: Develop a scale that characterizes the acute and long-term psychological effects of ketamine use among persons with ketamine dependence. Methods: We developed a preliminary symptom checklist...
Journal of Psychiatric Research
December 24, 2014
Ke Xu, John H. Krystal, Y. Ning et al.
65 citations
Objective Studies of the effects of the N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, ketamine, have suggested similarities to the symptoms of schizophrenia. Our primary goal was to evaluate the dimensions of the Positive and Negative Syndrome Scale (PANSS) in ketamine users (acute and chronic) compared to schizophrenia patients (early and chronic stages). Method We conducted...